Cytosorbents (NASDAQ:CTSO) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of Cytosorbents (NASDAQ:CTSO) in a report issued on Saturday. The firm issued a hold rating on the medical research company’s stock.

A number of other analysts have also recently weighed in on the stock. D. Boral Capital reiterated a “buy” rating and set a $10.00 price target on shares of Cytosorbents in a research note on Monday, January 13th. HC Wainwright restated a “neutral” rating and issued a $1.00 target price on shares of Cytosorbents in a research note on Monday, November 11th. Two research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $4.67.

Cytosorbents Price Performance

Shares of NASDAQ:CTSO opened at $1.15 on Friday. The stock has a market cap of $62.88 million, a P/E ratio of -3.19 and a beta of 0.61. The firm has a fifty day moving average price of $1.01 and a 200 day moving average price of $1.04. The company has a debt-to-equity ratio of 1.06, a current ratio of 1.97 and a quick ratio of 1.58. Cytosorbents has a 1-year low of $0.70 and a 1-year high of $1.61.

Institutional Trading of Cytosorbents

Several hedge funds have recently made changes to their positions in CTSO. Avenir Corp lifted its stake in shares of Cytosorbents by 4.0% in the fourth quarter. Avenir Corp now owns 3,093,946 shares of the medical research company’s stock valued at $2,815,000 after purchasing an additional 118,387 shares during the period. Skylands Capital LLC lifted its stake in shares of Cytosorbents by 1.0% in the fourth quarter. Skylands Capital LLC now owns 2,781,622 shares of the medical research company’s stock valued at $2,531,000 after purchasing an additional 26,195 shares during the period. Sargent Investment Group LLC lifted its stake in shares of Cytosorbents by 13.4% in the third quarter. Sargent Investment Group LLC now owns 1,626,247 shares of the medical research company’s stock valued at $2,439,000 after purchasing an additional 192,747 shares during the period. Geode Capital Management LLC lifted its stake in shares of Cytosorbents by 7.5% in the third quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock valued at $701,000 after purchasing an additional 32,415 shares during the period. Finally, Raymond James Financial Inc. acquired a new stake in shares of Cytosorbents in the fourth quarter valued at about $99,000. Institutional investors and hedge funds own 32.87% of the company’s stock.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.